Clinical Trial Update: Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) [Phase 2]

View source ↗

Summary

Phase 2 exploratory trial evaluating tumor cell contamination in leukapheresis products with and without Bortezomib in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Siddhartha Ganguly | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2021-06-18